Five Prime Therapeutics (FPRX) to present at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

• Headquarters: San Francisco, CA
• Founded: December 2001
• fiveprime.com

   

Five Prime Therapeutics announces Cabiralizumab Phase 1a/1b data abstract selected for late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

• The abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, has been selected for a late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland. Abstract Title: "First in Human Phase I Dose Escalation and Expansion of a novel combination, anti-CSF1-receptor (cabiralizumab) plus anti-PD-1 (nivolumab) in patients with advanced solid tumors."
• This will be the first presentation of clinical data on a combination of a CSF-1R antibody and a checkpoint inhibitor, to the Company's knowledge 
• In the Phase 1a/1b trial, Five Prime and Bristol-Myers Squibb are evaluating the safety, tolerability and preliminary efficacy of the combination in advanced solid tumors.

Five Prime Therapeutics (FPRX): 2-year performance

weekly chart

Five Prime Therapeutics (FPRX) : 2-year performance

 

Five Prime Therapeutics (FPRX) began trading on the NASDAQ on 18 September 2013

3/17/2014 chart update (daily)

Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company’s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

Address

Two Corporate Drive
SOUTH SAN FRANCISCO, CA 94080
United States 

Website 

http://www.fiveprime.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-207.75%	-276.42%
Operating margin	-210.17%	-278.51%
EBITD margin	-	-262.06%
Return on average assets	-45.55%	-53.75%
Return on average equity	-	-
Employees	107